Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (12) , 2040-2050
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
- Merck Sharp and Dohme United Kingdom
- Merck
- Clovis Oncology
- Novartis
- Daiichi-Sankyo
- F. Hoffmann-La Roche
- AstraZeneca
- Takeda Pharmaceuticals U.S.A.
- Genentech
- Janssen Pharmaceutica
- Bristol-Myers Squibb
- Teva Pharmaceutical Industries
- G1 Therapeutics
- Eli Lilly and Company
- AbbVie
- Pfizer
- Bayer Fund
- Roche
- Mirati Therapeutics
- Boehringer Ingelheim
- Sanofi
- Incyte
- Amgen
- EMD Serono
- Puma Biotechnology
This publication has 26 references indexed in Scilit:
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNAThe Journal of Molecular Diagnostics, 2018
- Resistance Mechanisms to Targeted Therapies inROS1+ andALK+ Non–small Cell Lung CancerClinical Cancer Research, 2018
- TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinibJournal of Thoracic Disease, 2018
- ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)Thoracic Cancer, 2018
- Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-AnalysisCurrent Respiratory Medicine Reviews, 2018
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyClinical Cancer Research, 2015
- Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerAnnals of Oncology, 2015
- Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)Lung Cancer, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014